Psychosomatic medicine
-
Psychosomatic medicine · Jul 2004
Randomized Controlled Trial Comparative Study Clinical TrialTreatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial.
To investigate efficacy and safety of St. John's wort (SJW) LI 160 in somatoform disorders. ⋯ Administration of 600 mg of SJW extract LI 160 daily is effective and safe in the treatment of somatoform disorders, thereby confirming results from a previous study.
-
Psychosomatic medicine · Jul 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialPsychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial.
Intervening in depression and/or low perceived social support within 28 days after myocardial infarction (MI) in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial did not increase event-free survival. The purpose of the present investigation was to conduct post hoc analyses on sex and ethnic minority subgroups to assess whether any treatment subgroup is at reduced or increased risk of greater morbidity/mortality. ⋯ White men, but not other subgroups, may have benefited from the ENRICHD intervention, suggesting that future studies need to attend to issues of treatment design and delivery that may have prevented benefit among sex and ethnic subgroups other than white men.
-
Psychosomatic medicine · Jul 2004
Comparative Study Clinical TrialPosttraumatic stress, nonadherence, and adverse outcome in survivors of a myocardial infarction.
Posttraumatic stress disorder (PTSD) symptoms have been reported in patients with coronary vascular disease, after the trauma of a myocardial infarction (MI). The effect of these symptoms on post-MI disease control has not been elucidated. We conducted a study that sought to determine whether PTSD symptoms post-MI are associated with increased likelihood of cardiovascular readmission and with nonadherence to treatment recommendations. ⋯ PTSD symptoms predicted poor disease control in this cohort of MI survivors. The data suggest that screening MI survivors for symptoms of PTSD may be beneficial if this high-risk population is to be targeted for interventions.